MilliporeSigma
  • Home
  • Search Results
  • Oral cancer/endothelial cell fusion experiences nuclear fusion and acquisition of enhanced survival potential.

Oral cancer/endothelial cell fusion experiences nuclear fusion and acquisition of enhanced survival potential.

Experimental cell research (2014-07-13)
Kai Song, Yong Song, Xiao-Ping Zhao, Hui Shen, Meng Wang, Ting-Lin Yan, Ke Liu, Zheng-Jun Shang
ABSTRACT

Most previous studies have linked cancer-macrophage fusion with tumor progression and metastasis. However, the characteristics of hybrid cells derived from oral cancer and endothelial cells and their involvement in cancer remained unknown. Double-immunofluorescent staining and fluorescent in situ hybridization (FISH) were performed to confirm spontaneous cell fusion between eGFP-labeled human umbilical vein endothelial cells (HUVECs) and RFP-labeled SCC9, and to detect the expression of vementin and cytokeratin 18 in the hybrids. The property of chemo-resistance of such hybrids was examined by TUNEL assay. The hybrid cells in xenografted tumor were identified by FISH and GFP/RFP dual-immunofluoresence staining. We showed that SCC9 cells spontaneously fused with cocultured endothelial cells, and the resultant hybrid cells maintained the division and proliferation activity after re-plating and thawing. Such hybrids expressed markers of both parental cells and became more resistant to chemotherapeutic drug cisplatin as compared to the parental SCC9 cells. Our in vivo data indicated that the hybrid cells contributed to tumor composition by using of immunostaining and FISH analysis, even though the hybrid cells and SCC9 cells were mixed with 1:10,000, according to the FACS data. Our study suggested that the fusion events between oral cancer and endothelial cells undergo nuclear fusion and acquire a new property of drug resistance and consequently enhanced survival potential. These experimental findings provide further supportive evidence for the theory that cell fusion is involved in cancer progression.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Anti-CDH1 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
Sigma-Aldrich
Anti-Cdh1 antibody,Mouse monoclonal, clone DCS-266, purified from hybridoma cell culture
Sigma-Aldrich
Monoclonal Anti-CDH1 antibody produced in mouse, clone 67A4, purified immunoglobulin, buffered aqueous solution
Sigma-Aldrich
Monoclonal Anti-CDH1 antibody produced in mouse, clone 3F4, purified immunoglobulin, buffered aqueous solution
Sigma-Aldrich
Anti-CDH1 antibody produced in rabbit, affinity isolated antibody
Sigma-Aldrich
Anti-CDH1 antibody produced in rabbit, affinity isolated antibody
Sigma-Aldrich
Monoclonal Anti-CDH1 antibody produced in mouse, Prestige Antibodies® Powered by Atlas Antibodies, clone CL1170, purified immunoglobulin, buffered aqueous glycerol solution
Sigma-Aldrich
Monoclonal Anti-CDH1 antibody produced in mouse, Prestige Antibodies® Powered by Atlas Antibodies, clone CL1172, purified immunoglobulin, buffered aqueous glycerol solution
Sigma-Aldrich
Monoclonal Anti-CDH1 antibody produced in mouse, Prestige Antibodies® Powered by Atlas Antibodies, clone CL1180, purified immunoglobulin, buffered aqueous glycerol solution
Sigma-Aldrich
Anti-CDH1 antibody produced in goat, affinity isolated antibody, buffered aqueous solution